Mitsubishi UFJ Asset Management
TCRT icon

Mitsubishi UFJ Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Mitsubishi UFJ Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-647
Closed -$177K – 1155
2021
Q3 		$177K Hold
647
– – ﹤0.01% 1079
2021
Q2 		$256K Sell
647
-249
-28% -$116K ﹤0.01% 1060
2021
Q1 		$484K Buy
896
+288
+47% +$179K ﹤0.01% 896
2020
Q4 		$230K Buy
608
+166
+38% +$66K ﹤0.01% 940
2020
Q3 		$167K Sell
442
-18
-4% -$7.95K ﹤0.01% 915
2020
Q2 		$226K Buy
460
+207
+82% +$92.3K ﹤0.01% 873
2020
Q1 		$93K Buy
253
+46
+22% +$23.8K ﹤0.01% 933
2019
Q4 		$139K Sell
207
-18
-8% -$12.4K ﹤0.01% 924
2019
Q3 		$145K Buy
225
+44
+24% +$34.9K ﹤0.01% 867
2019
Q2 		$158K Sell
181
-171
-49% -$118K ﹤0.01% 856
2019
Q1 		$204K Buy
352
+38
+12% +$15.9K ﹤0.01% 799
2018
Q4 		$101K Buy
314
+114
+57% +$45.1K ﹤0.01% 849
2018
Q3 		$96K Buy
+200
New +$85.8K ﹤0.01% 863

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mitsubishi UFJ Asset Management's TCRT Position: Q4 2021 in Review

Mitsubishi UFJ Asset Management sold out of Alaunos Therapeutics (TCRT) in Q4 2021, closing a stake of 647 shares — an estimated $177K sold.

Mitsubishi UFJ Asset Management first reported a position in TCRT in Q3 2018 and held it in 13 quarters. The position peaked at $484K in Q1 2021. 165 funds tracked by Wall St. Rank hold TCRT as of Q4 2021.

  • Mitsubishi UFJ Asset Management reported no remaining Alaunos Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Mitsubishi UFJ Asset Management sold 647 Alaunos Therapeutics shares in Q4 2021, an estimated $177K.
  • Mitsubishi UFJ Asset Management first reported a position in Alaunos Therapeutics in Q3 2018 and held it in 13 quarters.
  • Mitsubishi UFJ Asset Management's Alaunos Therapeutics position peaked at $484K in Q1 2021.
  • 165 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2021.

Based on Mitsubishi UFJ Asset Management's 13F filing for Q4 2021, filed 7 Feb 2022.